Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Memantine for Agitation in Dementia.

Trial Profile

Memantine for Agitation in Dementia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Memantine (Primary)
  • Indications Agitation; Alzheimer's disease
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms MAGD; MAGD-Genes
  • Most Recent Events

    • 30 Jan 2014 Accruel to date is 93% according to United Kingdom Clinical Research Network record (3986).
    • 22 Oct 2012 New source identified and integrated (ISRCTN: Current Controlled Trials: 24953404).
    • 18 Feb 2012 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network record (9420).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top